Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation

@article{Fujihara2007IntratumoralIO,
  title={Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation},
  author={Atsuko Fujihara and Masayuki Kurooka and Tsuneharu Miki and Yasufumi Kaneda},
  journal={Cancer Immunology, Immunotherapy},
  year={2007},
  volume={57},
  pages={73-84}
}
We have already demonstrated that inactivated, replication-defective Sendai virus particles (HVJ-E) have a powerful antitumor effect by both the generation of tumor-specific cytotoxic T cells and inhibition of regulatory T cell activity. Here, we report that HVJ-E also has an antitumor effect through non-T cell immunity. Microarray analysis revealed that direct injection of HVJ-E induced the expression of CXCL10 in established Renca tumors. CXCL10 was secreted by dendritic cells in the tumors… 
Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma
TLDR
HVJ-E enhanced effector T cell-mediated anti-tumor immunity induced by IL-2 through inhibition of Treg-mediated immunosuppression, showing promise as an attractive, novel immunogene therapy for malignant glioma.
Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
TLDR
Investigation of the therapeutic effects of Sendai virus particles carrying IL-2 gene in a mouse model of angiosarcoma found immunogene therapy with HVJ-E/IL-2 with or without sunitinib could be a promising therapeutic option for cutaneous angiosARcoma.
Inactivated Sendai virus suppresses murine melanoma growth by inducing host immune responses and down-regulating β-catenin expression.
TLDR
This is the first report to show the effective inhibition of melanoma tumors by HVJ-E alone and the mechanism through which it induces antitumor immune responses and regulates important signal pathways for melanoma invasion.
Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production
TLDR
IL-12–conjugated HVJ-E is a promising tool for the treatment of cancers, including lung metastasis by inducing local production of IFN-γ in the lungs and generating large numbers of melanoma-specific CTLs.
Cancer Therapy : Preclinical Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-g Production
Purpose: Cancer immunotherapy has encountered many difficulties in the face of the expectation to eradicate cancer, and new breakthroughs are required. We have previously shown that UV-inactivated
A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy
TLDR
Combination therapy consisting of HVJ-E and chemotherapy completely eradicated the tumor, and generated anti-tumor immunity, and the combination therapy could be a promising new strategy for cancer therapy.
Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application
TLDR
Several favorable results regarding the antitumor effects of HVJ-E are shown and the novel mechanism underlying this tumor immune response is described, which appears to include not only enhanced effector T cell- and/or natural killer cell-mediated immunity, but also rescue from regulatory T cell (Treg)-mediated immunosuppression.
Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope
TLDR
This combination shows promise as an attractive novel therapy for glioblastoma after a remarkable anti-tumor response was likely due to a synergistic effect of Eg5 siRNA and HVJ-E.
Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study
TLDR
Induction of antitumor immunity was observed: activation of natural killer cells, a marked increase in interferon-γ levels in the peripheral blood, and infiltration of cytotoxic T cells into both injected and noninjected tumor lesions, suggesting that HVJ-E might be a new treatment approach in patients with advanced melanoma.
Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in mice.
TLDR
A platelet vector incorporating viral particles, a Trojan horse for cancer treatment, will provide a new approach for cancer therapy using oncolytic viruses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
TLDR
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin–conjugated HVJ envelope vector
TLDR
CG-HVJ-E may suppress peritoneal dissemination of cancer and produce a high level of luciferase gene expression primarily within the tumor deposits when combined with cationized gelatin.
Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth
TLDR
It is shown that bioactive human interferon-inducible protein-10 (IP10) can be secreted from a variety of mammalian cells upon transduction with RCR vectors carrying the human IP10 gene, and that IP10 vector-affected tumors evidenced elevated levels of IL-12p35 mRNA.
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors.
TLDR
It is demonstrated that the TNF superfamily member, LIGHT, known as TNFSF14 and a T-cell costimulatory molecule, is a critical ligand for the activation of NK cells, establishing a direct role for LIGHT in NK activation/expansion and a critical helper role of activated NK cells in priming CD8+ T cells and breaking T- cell tolerance at the tumor site.
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.
TLDR
IP-10 is an antitumor agent that promotes damage in established tumor vasculature and causes tissue necrosis in human Burkitt lymphomas established subcutaneously in athymic mice.
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
  • F. Errington, A. Bateman, +7 authors A. Melcher
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
TLDR
FMG-expressing allogeneic tumor cells are a potent source of antitumor vaccines and represent novel strategies well-suited to clinical translation, demonstrating that syncitiosomes cannot account entirely for the mechanism of immune priming.
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
TLDR
It is reported that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis and a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences, were efficiently destroyed.
Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
TLDR
The role of intratumoral cytokine network in the understanding immunobiology of tumor-associated dendritic cells, which seems to possess different regulatory functions at the tumor site is discussed.
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
TLDR
HVJ envelope vector will be useful for both ex vivo and in vivo gene therapy experiments, and efficiency of gene transfer was greatly enhanced by protamine sulfate and centrifugation.
Development of HVJ Envelope Vector and Its Application to Gene Therapy.
TLDR
The HVJ envelope vector is a promising tool for both ex vivo and in vivo gene therapy experiments and a pilot plant to commercially produce clinical grade HVj envelope vector has been established.
...
1
2
3
4
5
...